Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Maria‐Luisa Schubert, Michael Schmitt, L. Wang, et al.
Annals of Oncology (2020) Vol. 32, Iss. 1, pp. 34-48
Open Access | Times Cited: 361

Showing 1-25 of 361 citing articles:

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Andréas Mackensen, Fabian Müller, Dimitrios Mougiakakos, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2124-2132
Closed Access | Times Cited: 563
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 290
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute, et al.
Nature Reviews Clinical Oncology (2022) Vol. 20, Iss. 1, pp. 49-62
Open Access | Times Cited: 249
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Xinyi Xiao, Shengkang Huang, Sifei Chen, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 163
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu‐Tian Xiao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 128
CAR-T cell combination therapy: the next revolution in cancer treatment
Maysoon Al‐Haideri, Santalia Banne Tondok, Salar Hozhabri Safa, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 88
How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
Michael D. Jain, Melody Smith, Nirali N. Shah
Blood (2023)
Open Access | Times Cited: 85
The Notch signaling pathway: a potential target for cancer immunotherapy
Xinxin Li, Xianchun Yan, Yufeng Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 85
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
Kitsada Wudhikarn, Miguel‐Angel Perales
Bone Marrow Transplantation (2022) Vol. 57, Iss. 10, pp. 1477-1488
Open Access | Times Cited: 80
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Mingzhi Zhang, Dan Chen, Xiaorui Fu, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 13, pp. 2830-2843
Open Access | Times Cited: 79
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Reuben Benjamin, Nitin Jain, Marcela V. Maus, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 11, pp. e833-e843
Closed Access | Times Cited: 79
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 59
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
Eleftheria Kampouri, Jessica S Little, Kai Rejeski, et al.
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Open Access | Times Cited: 54
The state of cell and gene therapy in 2023
Daniel Chancellor, David Barrett, Ly Nguyen-Jatkoe, et al.
Molecular Therapy (2023) Vol. 31, Iss. 12, pp. 3376-3388
Closed Access | Times Cited: 53
A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy
Jiaying Zhang, Bo Chen, Chunyuan Gan, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 7605-7635
Open Access | Times Cited: 49
Exosome-based delivery strategies for tumor therapy: an update on modification, loading, and clinical application
Qian Yang, Shisheng Li, Haibo Ou, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 45
Advancements and challenges in CAR T cell therapy in autoimmune diseases
Georg Schett, Fabian Müller, Jule Taubmann, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 9, pp. 531-544
Closed Access | Times Cited: 44
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
Martin Hoenigl, Amir Arastehfar, Maiken Cavling Arendrup, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 34
Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy
Ann E. Metzloff, Marshall S. Padilla, Ningqiang Gong, et al.
Advanced Materials (2024) Vol. 36, Iss. 26
Open Access | Times Cited: 31
Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions
Yan Zhong, Jingfeng Liu
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 19
CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)
Dahua Sun, Xiang Shi, Sanyan Li, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 3
Open Access | Times Cited: 18
The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors
Lihong Wang, Lufang Zhang, Louisa Chard Dunmall, et al.
Cancer Letters (2024) Vol. 591, pp. 216871-216871
Open Access | Times Cited: 18
Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination
Zhaokai Zhou, Yumiao Mai, Ge Zhang, et al.
Cancer Letters (2024) Vol. 598, pp. 217079-217079
Closed Access | Times Cited: 17
Novel strategies to manage CAR-T cell toxicity
Arthur Mulvey, Lionel Trueb, George Coukos, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
Advancements and Future Directions of Dual‐Target Chimeric Antigen Receptor T‐Cell Therapy in Preclinical and Clinical Studies
Chenyun Zhang, Haizhou Liu
Journal of Immunology Research (2025) Vol. 2025, Iss. 1
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top